Stephen Curtis

Steve completed his PhD in biological and biomedical sciences at Harvard Medical School in Boston. His doctoral studies focused on the cellular biology and genetics of lung cancer development, propagation, and progression. Steve graduated summa cum laude from Cornell University, earning a dual BS degree in molecular biology and applied economics and management. 

​

Steve has a personal interest in teaching and enabling students to expand their horizons across disciplines. To that end, he has served as a mentor to graduate students and postdoctoral fellows, giving them the ability to explore venture capital, entrepreneurship, and broader opportunities in the biotech industry. Additionally, Steve serves as an advisor to various incubator and accelerator programs.

Stephen joined MPM Capital in 2018, focusing on the firm's main BioVentures fund; he also supports the fund's other activities, including the Oncology Impact Fund. He is located in the firm's Cambridge, Massachusetts office. 

​

Previously, Stephen was Director of Business Development - Emerging Technology and Innovation for Eli Lilly & Company. The Emerging Technology and Innovation team complements therapeutic area-specific external research efforts and specializes in connecting partners to Lilly expertise and deploying flexible funding models. In addition to traditional business development activities, Steve focused on Lilly's strategic limited partnerships in venture funds, direct equity investments in selected biotechnology companies, "build-to-buy' investments, and other 'shared-risk' drug discovery and early development relationships. 

​

Prior to joining Lilly, Steve co-led the Bioscience Ventures group within 2M Companies, the Dallas-based family office of Morton H. Meyerson, focusing on Seed and Series A biotech investments and portfolio management. Before that, Steve ran the technology evaluation and in-licensing program at Reata Pharmaceuticals, leading cross-functional efforts to identify and acquire novel therapeutic programs within a variety of disease areas. Steve also interned at Siemens Venture Capital in Boston, analyzing markets of strategic interest.

Steve is a member of Class 20, and served the majority of his fellowship at 2M Companies under the mentorship of Melissa Krauth, former Principal of the firm's bioscience ventures group, and completed his fellowship at Eli Lilly & Co.